Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A, et al. - In adults aged 60 years and older, a third BNT162b2 dose (SARS-CoV-2 vaccine) was found to be linked with significantly elevated IgG titers after 10 to 19 days, with no major adverse events.

• In 97 persons aged 60 years and older (61% were women), antispike IgG antibody titers were evaluated prior to (August 4-12, 2021) and following (August 16-24, 2021) a third BNT162b2 dose.

• A total of 94 participants (97%) were seropositive prior to the third dose.

• Following the third dose, a significant increase occurred in the median titer level, from a median of 440 AU/mL to 25 468 AU/mL, and seropositivity was evident in all participants.

• There was no significant correlation between age and IgG titers.

• No major adverse events were documented.